Drug intelligence / Profile preview

ZNF304 siRNA-DANP

Development stage: Preclinical
Lead developer: University of Texas MD Anderson Cancer Center
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
Administration: Intravenous, Intraperitoneal

Overview

ZNF304 siRNA-DANP is an experimental RNA interference therapeutic consisting of a small interfering RNA (siRNA) targeting the transcription factor ZNF304, encapsulated within a dual assembly nanoparticle (DANP). The DANP delivery system features a chitosan-tripolyphosphate inner core and a polylactic acid (PLA) outer coating, designed for sustained release and prolonged gene silencing (up to two weeks from a single dose). ZNF304 is a Kruppel-associated box (KRAB)-zinc finger protein that transcriptionally regulates Integrin beta 1 (ITGB1). By silencing ZNF304, the drug reduces ITGB1 expression, thereby sensitizing ovarian cancer cells to anoikis (detachment-induced apoptosis), inhibiting migration, and reducing tumor growth and microvessel density. It is primarily being investigated for the treatment of high-grade serous ovarian carcinoma.

Other names: ZNF304 siRNA-loaded DANPZNF-304 siRNA-loaded DANPZNF 304 siRNA-loaded DANPDANP-ZNF304 siRNADANP-ZNF-304 siRNADANP-ZNF 304 siRNA

Targets

ZNF304 (Zinc finger protein 304)

Beyond the preview

Go deeper on ZNF304 siRNA-DANP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZNF304 siRNA-DANP.

Explore the full profile